Home/Pipeline/TBI-1401 (HSV-TK/GCV)

TBI-1401 (HSV-TK/GCV)

Hematological malignancies (haploidentical HSCT)

Phase 3Active

Key Facts

Indication
Hematological malignancies (haploidentical HSCT)
Phase
Phase 3
Status
Active
Company

About Takara Bio

Takara Bio is a global biotechnology company with a mission to contribute to the advancement of life sciences and the improvement of human health. It has established itself as a key provider of research reagents, instruments, and contract development and manufacturing (CDMO) services, particularly in the fields of cell and gene therapy. The company's strategic direction focuses on expanding its therapeutic pipeline, scaling its CDMO capabilities, and deepening its research tools portfolio to address growing market demands in precision medicine.

View full company profile